Table 2 Rates of overall and nodal pathologic complete response in BRCA carriers and noncarriers

From: Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers

 

Overall pCR n/N (%)

Nodal pCR n/N (%)

BRCA1

BRCA2

Noncarrier

BRCA1

BRCA2

Noncarrier

All subtypes

39/92 (42%)

15/73 (21%)

317/1261(25%)

31/48 (65%)

22/48 (46%)

371/856 (43%)

HR+/HER2−

8/21 (38%)

2/38 (5%)

30/463 (7%)

5/12 (42%)

10/30 (33%)

73/370 (20%)

HR+/HER2+

0/4 (0%)

1/6 (17%)

97/307 (32%)

0/2 (0)

0/4 (0)

101/167 (61%)

HR−/HER2+

0/0 (0%)

1/2 (50%)

109/174 (62%)

0/0 (0%)

1/1 (100%)

110/128 (85%)

TNBC

31/67 (46%)

11/27 (41%)

91/317 (29%)

26/34 (76%)

11/13 (85%)

87/191 (46%)

  1. pCR pathologic complete response, HR hormone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer.
Back to article page